Le Lézard
Classified in: Mining industry, Health, Science and technology
Subject: ATY

WeissLaw LLP Reminds CCR, TCO, UROV, and PTI Shareholders About Its Ongoing Investigations


NEW YORK, Nov. 30, 2020 /PRNewswire/ --

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

CONSOL Coal Resources LP (NYSE: CCR)

WeissLaw LLP is investigating possible breaches of the limited partnership agreement, fiduciary duty and other violations of law by the board of directors of CONSOL Coal Resources LP (NYSE: CCR) in connection with the proposed acquisition of CCR by CONSOL Energy Inc. ("CEIX").  Under the terms of the agreement, CCR unitholders will receive 0.73 shares of CEIX for each CCR unit they own, representing implied per-share merger consideration of $4.15, based upon CEIX's November 27, 2020 closing price of $5.68.  If you own CCR units and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/ccr/  

Taubman Centers, Inc. (NYSE: TCO)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Taubman Centers, Inc. (NYSE: TCO) in connection with the revised acquisition of the company by Simon Property Group, Inc.  Under the terms of the revised agreement, shareholders will receive only $43.00 for each share of TCO they own, representing a significant reduction from the $52.50 per share that the parties had originally agreed to in February 2020.  If you own TCO shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/tco/

Urovant Sciences Ltd. (NASDAQ: UROV)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Urovant Sciences Ltd. (NASDAQ: UROV) in connection with the proposed interested-party acquisition of the company by Sumitovant Biopharma Ltd., UROV's majority shareholder that currently owns 72% of the company's outstanding common shares.  Under the terms of the acquisition agreement, the company's shareholders will receive only $16.25 in cash for each share of UROV common stock that they own.   If you own UROV shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslawllp.com/urov/ 

Proteostasis Therapeutics, Inc. (NASDAQ: PTI)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Proteostasis Therapeutics, Inc. (NASDAQ: PTI) in connection with the company's proposed merger with Yumanity Therapeutics, Inc. ("Yumanity").  Under the terms of the agreement, PTI will acquire all outstanding shares of Yumanity in exchange for newly-issued shares of PTI common stock, with existing PTI shareholders owning only 32.5% of the new entity.  If you own PTI shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/proteostasis-therapeutics-inc/

SOURCE WeissLaw LLP


These press releases may also interest you

at 10:05
The "Inspection Machines Market by Product (Vision Inspection, Checkweigher, Metal Detector, Software), Type (Manual, Automatic), Packaging Type (Vials, Syringes, Blisters), End User (Pharmaceutical, Medical Device), COVID-19 Impact - Global Forecast...

at 10:05
Zoetis Inc. today announced that it received a score of 100 percent on the Human Rights Campaign Foundation's 2021 Corporate Equality Index (CEI), the nation's foremost benchmarking survey and report measuring corporate policies and practices...

at 10:05
Venatorx Pharmaceuticals today announced that Chitrananda Abeygunawardana, Ph.D. has been named Vice President, Regulatory Affairs. With nearly 25 years' experience in pharmaceutical research, regulatory affairs and compliance, Dr. Abey will be...

at 10:01
Hundreds of medical products have been authorized for temporary use in the past year to meet the unprecedented need for life-saving equipment and supplies during the COVID-19 pandemic. Today, an internationally respected patient safety organization...

at 10:00
Government of Canada officials will hold a technical briefing to provide an overview on the roll-out of COVID-19 vaccines. Officials will be available to answer questions from the media following their remarks. DateJanuary 28, 2021 Time12:00 PM (EST)...

at 10:00
Effective Jan. 1, 2021, Garrett Lewis has been named Chief Operating Officer for VCA Animal Hospitals. The newly created role more closely aligns functions that drive growth for veterinary services leader VCA ? which cares for 4 million pets each...



News published on 30 november 2020 at 20:45 and distributed by: